BG Medicine, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 20, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq: BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Eric Bouvier, BG Medicine's President and CEO, will presenting at the 24th Annual Piper Jaffray Healthcare Conference on November 27 at 3:00 PM Eastern Time (ET) in New York City.
The fireside chat style presentation will be webcast live and archived for 30 days on BG Medicine's Investor Relations website at ir.BG-medicine.com.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq: BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company's first commercialized product, the BGM Galectin-3® test for use in patients with chronic heart failure, is available in the United States and Europe. BG Medicine is also developing the CardioSCORETM test, a blood test designed to aid in the assessment of an individual's risk for near-term major cardiovascular events. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352 .